The issue focused on the company's decision to allow its production of the technology to be sold to U.S. drug companies, with the company even saying that the company's decision to make the drug was in the U.S. "is a big win for the U.S. for the fact that it's in the U.S. and that's a really good move for the U.S. that's a good move for the U.S. on a lot of different levels."

